On target with last year, a total of 87% of funds recorded in 2021 through biopharma collaborations with nonprofit entities by the end of October are focused on COVID-19 pandemic efforts. The pandemic accounts for 54% of the money collected through grants, which is still a sturdy amount but down from 76% in 2020.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aivita, Awakn, Biontech, Bridgebio, Curacle, Eton, Gilead, Innovent, Merck, Neocura, Pfizer, Polyphor, PF Argentum, Trillium.
Plants could be an alternative vaccine platform for both COVID-19 and future pandemics, shaking up a biologics sector that is currently mostly protein-based. South Korean company Bioapplications Inc., for example, is aiming to have a plant-derived booster shot for COVID-19 in the clinic in 2022.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Agenus, Axial, Bharat, Biontech, Bio-Path, Eli Lilly, Medicenna, Novartis, Novavax, Ocugen, Pfizer, Quell, Vitti.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Angel, Atamyo, Axcella, Biovie, Corvus, Emmaus, Geron, Mereo, Moderna, Nova Mentis, Precigen, Seagen.
RSS
